Compare Ginkgo Bioworks Holdings Inc (DNA) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Tripadvisor Inc Common Stock — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Tripadvisor Inc Common Stock trades at $14.42 (market cap $1.63B). The key difference: Tripadvisor Inc Common Stock is far larger — about 2.8× Ginkgo Bioworks Holdings Inc's market cap, and Tripadvisor Inc Common Stock is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | TRIP | |
|---|---|---|
Market Cap | $590.53M | $1.63B |
Sector | Health | Consumer Cyclical |
52-Week High | $16.14 | $19.14 |
52-Week Low | $5.48 | $9.24 |
Enterprise Value | $627.78M | $1.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Tripadvisor (TRIP) trades at $14.40, up 3.0% today, with technical indicators showing bullish momentum. The company reported mixed Q2 2026 earnings, missing expectations in two of the last three quarters. Recent news highlights the $700 million sale of TheFork to American Express, which may provide capital flexibility. Revenue grew to $1.89 billion in 2025, though net margins remain thin at 0.99%. Analyst consensus is mixed with 60.7% hold ratings and a $13.87 price target slightly below current levels.
The outlook is cautious due to competitive pressures and inconsistent earnings, but the stock shows technical strength. Opportunities include potential benefits from the TheFork sale and travel sector recovery. Key risks are macroeconomic headwinds and execution challenges in core segments. Investors should weigh solid cash flow against high P/E valuation and analyst skepticism for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
